A prospective clinical trial of 60 grade IV glioma patients showed lack of efficacy of enzastaurin (a PKC and PI-3 kinase/Akt inhibitor) but a secondary analysis revealed a strong prognostic influence of resection on overall survival [29]. This evidence concerns the gene PRRT2 and central nervous system cancer.